Revenue Breakdown
Composition ()
No data
Revenue Streams
Profitability & Margins
Evaluating the bottom line, Lyell Immunopharma Inc maintains a gross margin of 100.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -248353.33%, while the net margin is -258973.33%. These profitability ratios, combined with a Return on Equity (ROE) of -75.75%, provide a clear picture of how effectively LYEL converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, LYEL competes directly with industry leaders such as PRTA and NGEN. With a market capitalization of $524.94M, it holds a leading position in the sector. When comparing efficiency, LYEL's gross margin of 100.00% stands against PRTA's 100.00% and NGEN's N/A. Such benchmarking helps identify whether Lyell Immunopharma Inc is trading at a premium or discount relative to its financial performance.
